查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1266323

白血病治療市場：按類型、藥物類別和分銷渠道分類：2021-2031 年全球機會分析和行業預測

Leukemia Therapeutics Market By Type, By Drug Class, By Distribution channel : Global Opportunity Analysis and Industry Forecast, 2021-2031
出版日期: | 出版商: Allied Market Research | 英文 392 Pages | 商品交期: 2-3個工作天內

價格

2021 年全球白血病治療市場價值 781863 萬美元，預計 2031 年將達到 141億6248 萬美元，2022 年至 2031 年的複合年增長率為 6.1%。

白血病是一種影響血液和骨髓的血癌。 它的特點是異常白細胞不受控制地產生，會干擾血液和免疫系統的正常功能。 白血病的類型包括急性淋巴細胞白血病 (ALL)、急性髓性白血病 (AML)、慢性淋巴細胞白血病 (CLL) 和慢性粒細胞白血病 (CML)。 罕見類型的白血病包括慢性粒單核細胞白血病 (CMML) 和幼年粒單核細胞白血病 (JMML)。 根據白血病的類型和階段以及患者的健康狀況，這些罕見類型的白血病的治療可能與化療等相結合。 白血病的症狀包括疲勞、虛弱、頻繁感染以及容易瘀傷和出血。

許多非處方藥已被開髮用於治療白血病，推動了對白血病治療的需求。 一些最常用的藥物包括 Gleevec、Bosulif、Sprycel 和 Iculsig。 這些藥物在治療白血病方面顯示出了巨大的療效，並已成為許多患者的標準治療。 此外，用於治療白血病的新型和改進藥物的開發正在推動對白血病治療的需求。

由於全球白血病患者數量的增加和骨髓活檢數量的增加，白血病治療市場正在增長。 此外，白血病研發活動投入的增加以及人們對靶向治療意識的增強進一步推動了白血病治療市場的增長。 新藥的推出提高了白血病患者的生存率，增加了他們戰勝白血病的機會，進一步推動了市場增長。

另一方面，白血病治療的監管審批很緊，白血病治療藥物的副作用阻礙了市場增長。 例如，Onureg（阿扎胞甘）會導致白血病患者頭暈、噁心、嘔吐、疲勞、貧血和血小板計數低。 此外，用於治療白血病的藥物專利到期和高昂的治療費用也限制了全球白血病治療市場的增長。 此外，越來越多的白血病臨床試驗和新產品批准有望不僅在新興市場，而且在發達市場創造新的機會。 例如，2020年12月，安進宣布美國食品藥品監督管理局（FDA）批准利妥昔單抗（rituximab）的生物仿製藥RIABNI（rituximab-arrx）用於治療成年慢性淋巴細胞白血病（CLL）患者。

內容

第 1 章介紹

第 2 章執行摘要

第 3 章市場概述

  • 市場定義和範圍
  • 主要發現
    • 頂級影響因子
    • 頂級投資基金
  • 波特的五力分析
    • 供應商的議價能力
    • 買家的議價能力
    • 替代品的威脅
    • 新進入者的威脅
    • 競爭對手的實力
  • 市場動態
    • 促進因素
      • 白血病發病率增加
      • 提高產品批准率
    • 抑制因素
      • 白血病治療的副作用和副作用
      • 白血病治療費用高昂
    • 機會
      • 新興經濟體的高增長潛力
      • 增加研發活動
  • 分析 COVID-19 對市場的影響

第 4 章白血病治療市場：按類型

  • 概覽
    • 市場規模和預測
  • 急性淋巴細胞白血病
    • 主要市場趨勢、增長動力和機遇
    • 市場規模和預測：按地區
    • 市場份額分析：國家/地區分析
  • 急性髓性白血病
    • 主要市場趨勢、增長動力和機遇
    • 市場規模和預測：按地區
    • 市場份額分析：國家/地區分析
  • 慢性淋巴細胞白血病
    • 主要市場趨勢、增長動力和機遇
    • 市場規模和預測：按地區
    • 市場份額分析：國家/地區分析
  • 慢性粒細胞白血病
    • 主要市場趨勢、增長動力和機遇
    • 市場規模和預測：按地區
    • 市場份額分析：國家/地區分析
  • 其他
    • 主要市場趨勢、增長動力和機遇
    • 市場規模和預測：按地區
    • 市場份額分析：國家/地區分析

第 5 章白血病治療市場：按藥物類別分類

  • 概覽
    • 市場規模和預測
  • 化療
    • 主要市場趨勢、增長動力和機遇
    • 市場規模和預測：按地區
    • 市場份額分析：國家/地區分析
  • 靶向治療和免疫治療
    • 主要市場趨勢、增長動力和機遇
    • 市場規模和預測：按地區
    • 市場份額分析：國家/地區分析

第 6 章白血病治療市場：按分銷渠道

  • 概覽
    • 市場規模和預測
  • 醫院藥房
    • 主要市場趨勢、增長動力和機遇
    • 市場規模和預測：按地區
    • 市場份額分析：國家/地區分析
  • 藥店和商店式配藥店
    • 主要市場趨勢、增長動力和機遇
    • 市場規模和預測：按地區
    • 市場份額分析：國家/地區分析
  • 在線提供商
    • 主要市場趨勢、增長動力和機遇
    • 市場規模和預測：按地區
    • 市場份額分析：國家/地區分析

第 7 章白血病治療市場：按地區

  • 概覽
    • 市場規模和預測：按地區
  • 北美
    • 主要趨勢和機會
    • 市場規模/預測：按類型
    • 市場規模和預測：按藥物類別
    • 市場規模和預測：按分銷渠道
    • 市場規模/預測：按國家/地區分類
      • 美國
      • 主要市場趨勢、增長動力和機遇
      • 市場規模/預測：按類型
      • 市場規模和預測：按藥物類別
      • 市場規模和預測：按分銷渠道
      • 加拿大
      • 主要市場趨勢、增長動力和機遇
      • 市場規模/預測：按類型
      • 市場規模和預測：按藥物類別
      • 市場規模和預測：按分銷渠道
      • 墨西哥
      • 主要市場趨勢、增長動力和機遇
      • 市場規模/預測：按類型
      • 市場規模和預測：按藥物類別
      • 市場規模和預測：按分銷渠道
  • 歐洲
    • 主要趨勢和機會
    • 市場規模/預測：按類型
    • 市場規模和預測：按藥物類別
    • 市場規模和預測：按分銷渠道
    • 市場規模/預測：按國家/地區分類
      • 德國
      • 主要市場趨勢、增長動力和機遇
      • 市場規模/預測：按類型
      • 市場規模和預測：按藥物類別
      • 市場規模和預測：按分銷渠道
      • 法國
      • 主要市場趨勢、增長動力和機遇
      • 市場規模/預測：按類型
      • 市場規模和預測：按藥物類別
      • 市場規模和預測：按分銷渠道
      • 英國
      • 主要市場趨勢、增長動力和機遇
      • 市場規模/預測：按類型
      • 市場規模和預測：按藥物類別
      • 市場規模和預測：按分銷渠道
      • 意大利
      • 主要市場趨勢、增長動力和機遇
      • 市場規模/預測：按類型
      • 市場規模和預測：按藥物類別
      • 市場規模和預測：按分銷渠道
      • 西班牙
      • 主要市場趨勢、增長動力和機遇
      • 市場規模/預測：按類型
      • 市場規模和預測：按藥物類別
      • 市場規模和預測：按分銷渠道
      • 其他歐洲
      • 主要市場趨勢、增長動力和機遇
      • 市場規模/預測：按類型
      • 市場規模和預測：按藥物類別
      • 市場規模和預測：按分銷渠道
  • 亞太地區
    • 主要趨勢和機會
    • 市場規模/預測：按類型
    • 市場規模和預測：按藥物類別
    • 市場規模和預測：按分銷渠道
    • 市場規模/預測：按國家/地區分類
      • 日本
      • 主要市場趨勢、增長動力和機遇
      • 市場規模/預測：按類型
      • 市場規模和預測：按藥物類別
      • 市場規模和預測：按分銷渠道
      • 中國
      • 主要市場趨勢、增長動力和機遇
      • 市場規模/預測：按類型
      • 市場規模和預測：按藥物類別
      • 市場規模和預測：按分銷渠道
      • 印度
      • 主要市場趨勢、增長動力和機遇
      • 市場規模/預測：按類型
      • 市場規模和預測：按藥物類別
      • 市場規模和預測：按分銷渠道
      • 澳大利亞
      • 主要市場趨勢、增長動力和機遇
      • 市場規模/預測：按類型
      • 市場規模和預測：按藥物類別
      • 市場規模和預測：按分銷渠道
      • 韓國
      • 主要市場趨勢、增長動力和機遇
      • 市場規模/預測：按類型
      • 市場規模和預測：按藥物類別
      • 市場規模和預測：按分銷渠道
      • 其他亞太地區
      • 主要市場趨勢、增長動力和機遇
      • 市場規模/預測：按類型
      • 市場規模和預測：按藥物類別
      • 市場規模和預測：按分銷渠道
  • 拉美
    • 主要趨勢和機會
    • 市場規模/預測：按類型
    • 市場規模和預測：按藥物類別
    • 市場規模和預測：按分銷渠道
    • 市場規模/預測：按國家/地區分類
      • 巴西
      • 主要市場趨勢、增長動力和機遇
      • 市場規模/預測：按類型
      • 市場規模和預測：按藥物類別
      • 市場規模和預測：按分銷渠道
      • 沙特阿拉伯
      • 主要市場趨勢、增長動力和機遇
      • 市場規模/預測：按類型
      • 市場規模和預測：按藥物類別
      • 市場規模和預測：按分銷渠道
      • 南非
      • 主要市場趨勢、增長動力和機遇
      • 市場規模/預測：按類型
      • 市場規模和預測：按藥物類別
      • 市場規模和預測：按分銷渠道
      • LAMEA 的其餘部分
      • 主要市場趨勢、增長動力和機遇
      • 市場規模/預測：按類型
      • 市場規模和預測：按藥物類別
      • 市場規模和預測：按分銷渠道

第 8 章競爭格局

  • 介紹
  • 關鍵成功策略
  • 10 家主要公司的產品映射
  • 比賽儀表板
  • 競爭熱圖
  • 定位頂級公司，2021 年

第 9 章公司簡介

  • Abbvie Inc
  • Amgen Inc.
  • Pfizer Inc.
  • Novartis AG
  • Gilead Sciences, Inc.
  • Bristol-Myers Squibb Company
  • Sanofi
  • Teva Pharmaceutical Industries Limited
  • Lupin
  • Takeda Pharmaceutical Company Limited
Product Code: A01128

The global leukemia therapeutics market valued for $7,818.63 million in 2021 and is estimated to reach $14,162.48 million by 2031, exhibiting a CAGR of 6.1% from 2022 to 2031.  

Leukemia is a type of blood cancer that affects the blood and bone marrow. It is characterized by the uncontrolled production of abnormal white blood cells, which can interfere with the normal functioning of the blood and the immune system. There are several types of leukemia, including acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), and chronic myeloid leukemia (CML). The rare types of leukemia include chronic myelomonocytic leukemia (CMML), and juvenile myelomonocytic leukemia (JMML). Treatment for these rare forms of leukemia may involve a combination of chemotherapy, and others treatment depending on the type and stage of the leukemia and the overall health of the patient. Symptoms of leukemia can include fatigue, weakness, frequent infections, and easy bruising or bleeding.

A number of commercially available drugs have been developed to treat leukemia and are driving the demand for leukemia therapeutics. Some of the most commonly used drugs include Gleevec, Bosulif, Sprycel, Iculsig, and others. These drugs have shown significant efficacy in the treatment of leukemia and have become the standard of care for many patients. In addition, the development of new and improved drugs for the treatment of leukemia drives the demand for leukemia therapeutics.

The leukemia therapeutics market is experiencing growth owing to rise in cases of leukemia and the number of bone marrow biopsies across the world. In addition, the increase in investment in the R&D activities for leukemia and rise in awareness of the targeted therapies among the population further drive the growth of the leukemia therapeutics market. The introduction of new drugs has led to improved survival rates for patients with leukemia, giving them a better chance of beating the disease which further supports the market growth.

In contrast, the stringent regulatory approvals for the leukemia therapeutics and the side effect of the drugs used in the leukemia treatment impedes the growth of the market. For instance, Onureg (azacitidine) causes dizziness, nausea, vomiting, fatigue, anemia, and low platelet count in patients with leukemia. In addition, patent expiry of the drugs used in the treatment of leukemia and the higher costs involved in the therapies limit the growth of the global leukemia therapeutics market. Moreover, the rise in number of clinical trials for leukemia and new product approvals are anticipated to create newer opportunities in the emerging as well as the developed markets. For instance, in December 2020, Amgen announced the U.S. Food and Drug Administration (FDA) has approved RIABNI (rituximab-arrx), a biosimilar to Rituxan (rituximab), for the treatment of adult patients with chronic lymphocytic leukemia (CLL).

The global leukemia therapeutics market is segmented into type, drug class, distribution channel, and region. By type, the market is categorized into acute lymphocytic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, chronic myeloid leukemia, and others. On the basis of drug class, the market is segregated into chemotherapy, and targeted & immunotherapy. By distribution channel, the market is classified into hospital pharmacies, drug stores & retail pharmacies, and online providers. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).  

Major key players that operate in the global leukemia therapeutics market are: AbbVie Inc. Amgen Inc., Bristol-Myers Squibb Company, Gilead Sciences, Inc., Lupin, Novartis AG, Pfizer Inc., Sanofi, Takeda Pharmaceutical Company Limited, and Teva Pharmaceutical Industries Limited. 

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the global leukemia therapeutics market analysis from 2021 to 2031 to identify the prevailing global leukemia therapeutics market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the global leukemia therapeutics market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global leukemia therapeutics market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Type

  • Acute Lymphocytic Leukemia
  • Acute Myeloid Leukemia
  • Chronic Lymphocytic Leukemia
  • Chronic Myeloid Leukemia
  • Others

By Drug Class

  • Chemotherapy
  • Targeted Therapy and Immunotherapy

By Distribution channel

  • Hospital Pharmacies
  • Drug Store and Retail Pharmacies
  • Online Providers

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

Key Market Players

  • Amgen Inc.
  • Bristol-Myers Squibb Company
  • Lupin
  • Sanofi
  • Gilead Sciences, Inc.
  • Takeda Pharmaceutical Company Limited
  • Abbvie Inc
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Limited
  • Novartis AG

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key market segments
  • 1.3. Key benefits to the stakeholders
  • 1.4. Research Methodology
    • 1.4.1. Primary research
    • 1.4.2. Secondary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top impacting factors
    • 3.2.2. Top investment pockets
  • 3.3. Porter's five forces analysis
    • 3.3.1. Bargaining power of suppliers
    • 3.3.2. Bargaining power of buyers
    • 3.3.3. Threat of substitutes
    • 3.3.4. Threat of new entrants
    • 3.3.5. Intensity of rivalry
  • 3.4. Market dynamics
    • 3.4.1. Drivers
      • 3.4.1.1. Rise in incidences of leukemia
      • 3.4.1.2. Rise in product approval
    • 3.4.2. Restraints
      • 3.4.2.1. Side-effects and adverse reactions of leukemia therapeutics
      • 3.4.2.2. High cost of leukemia therapeutics
    • 3.4.3. Opportunities
      • 3.4.3.1. High growth potential in developing economies
      • 3.4.3.2. Increase in R&D activities
  • 3.5. COVID-19 Impact Analysis on the market

CHAPTER 4: LEUKEMIA THERAPEUTICS MARKET, BY TYPE

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. Acute Lymphocytic Leukemia
    • 4.2.1. Key market trends, growth factors and opportunities
    • 4.2.2. Market size and forecast, by region
    • 4.2.3. Market share analysis by country
  • 4.3. Acute Myeloid Leukemia
    • 4.3.1. Key market trends, growth factors and opportunities
    • 4.3.2. Market size and forecast, by region
    • 4.3.3. Market share analysis by country
  • 4.4. Chronic Lymphocytic Leukemia
    • 4.4.1. Key market trends, growth factors and opportunities
    • 4.4.2. Market size and forecast, by region
    • 4.4.3. Market share analysis by country
  • 4.5. Chronic Myeloid Leukemia
    • 4.5.1. Key market trends, growth factors and opportunities
    • 4.5.2. Market size and forecast, by region
    • 4.5.3. Market share analysis by country
  • 4.6. Others
    • 4.6.1. Key market trends, growth factors and opportunities
    • 4.6.2. Market size and forecast, by region
    • 4.6.3. Market share analysis by country

CHAPTER 5: LEUKEMIA THERAPEUTICS MARKET, BY DRUG CLASS

  • 5.1. Overview
    • 5.1.1. Market size and forecast
  • 5.2. Chemotherapy
    • 5.2.1. Key market trends, growth factors and opportunities
    • 5.2.2. Market size and forecast, by region
    • 5.2.3. Market share analysis by country
  • 5.3. Targeted Therapy and Immunotherapy
    • 5.3.1. Key market trends, growth factors and opportunities
    • 5.3.2. Market size and forecast, by region
    • 5.3.3. Market share analysis by country

CHAPTER 6: LEUKEMIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL

  • 6.1. Overview
    • 6.1.1. Market size and forecast
  • 6.2. Hospital Pharmacies
    • 6.2.1. Key market trends, growth factors and opportunities
    • 6.2.2. Market size and forecast, by region
    • 6.2.3. Market share analysis by country
  • 6.3. Drug Store and Retail Pharmacies
    • 6.3.1. Key market trends, growth factors and opportunities
    • 6.3.2. Market size and forecast, by region
    • 6.3.3. Market share analysis by country
  • 6.4. Online Providers
    • 6.4.1. Key market trends, growth factors and opportunities
    • 6.4.2. Market size and forecast, by region
    • 6.4.3. Market share analysis by country

CHAPTER 7: LEUKEMIA THERAPEUTICS MARKET, BY REGION

  • 7.1. Overview
    • 7.1.1. Market size and forecast By Region
  • 7.2. North America
    • 7.2.1. Key trends and opportunities
    • 7.2.2. Market size and forecast, by Type
    • 7.2.3. Market size and forecast, by Drug Class
    • 7.2.4. Market size and forecast, by Distribution channel
    • 7.2.5. Market size and forecast, by country
      • 7.2.5.1. U.S.
      • 7.2.5.1.1. Key market trends, growth factors and opportunities
      • 7.2.5.1.2. Market size and forecast, by Type
      • 7.2.5.1.3. Market size and forecast, by Drug Class
      • 7.2.5.1.4. Market size and forecast, by Distribution channel
      • 7.2.5.2. Canada
      • 7.2.5.2.1. Key market trends, growth factors and opportunities
      • 7.2.5.2.2. Market size and forecast, by Type
      • 7.2.5.2.3. Market size and forecast, by Drug Class
      • 7.2.5.2.4. Market size and forecast, by Distribution channel
      • 7.2.5.3. Mexico
      • 7.2.5.3.1. Key market trends, growth factors and opportunities
      • 7.2.5.3.2. Market size and forecast, by Type
      • 7.2.5.3.3. Market size and forecast, by Drug Class
      • 7.2.5.3.4. Market size and forecast, by Distribution channel
  • 7.3. Europe
    • 7.3.1. Key trends and opportunities
    • 7.3.2. Market size and forecast, by Type
    • 7.3.3. Market size and forecast, by Drug Class
    • 7.3.4. Market size and forecast, by Distribution channel
    • 7.3.5. Market size and forecast, by country
      • 7.3.5.1. Germany
      • 7.3.5.1.1. Key market trends, growth factors and opportunities
      • 7.3.5.1.2. Market size and forecast, by Type
      • 7.3.5.1.3. Market size and forecast, by Drug Class
      • 7.3.5.1.4. Market size and forecast, by Distribution channel
      • 7.3.5.2. France
      • 7.3.5.2.1. Key market trends, growth factors and opportunities
      • 7.3.5.2.2. Market size and forecast, by Type
      • 7.3.5.2.3. Market size and forecast, by Drug Class
      • 7.3.5.2.4. Market size and forecast, by Distribution channel
      • 7.3.5.3. UK
      • 7.3.5.3.1. Key market trends, growth factors and opportunities
      • 7.3.5.3.2. Market size and forecast, by Type
      • 7.3.5.3.3. Market size and forecast, by Drug Class
      • 7.3.5.3.4. Market size and forecast, by Distribution channel
      • 7.3.5.4. Italy
      • 7.3.5.4.1. Key market trends, growth factors and opportunities
      • 7.3.5.4.2. Market size and forecast, by Type
      • 7.3.5.4.3. Market size and forecast, by Drug Class
      • 7.3.5.4.4. Market size and forecast, by Distribution channel
      • 7.3.5.5. Spain
      • 7.3.5.5.1. Key market trends, growth factors and opportunities
      • 7.3.5.5.2. Market size and forecast, by Type
      • 7.3.5.5.3. Market size and forecast, by Drug Class
      • 7.3.5.5.4. Market size and forecast, by Distribution channel
      • 7.3.5.6. Rest of Europe
      • 7.3.5.6.1. Key market trends, growth factors and opportunities
      • 7.3.5.6.2. Market size and forecast, by Type
      • 7.3.5.6.3. Market size and forecast, by Drug Class
      • 7.3.5.6.4. Market size and forecast, by Distribution channel
  • 7.4. Asia-Pacific
    • 7.4.1. Key trends and opportunities
    • 7.4.2. Market size and forecast, by Type
    • 7.4.3. Market size and forecast, by Drug Class
    • 7.4.4. Market size and forecast, by Distribution channel
    • 7.4.5. Market size and forecast, by country
      • 7.4.5.1. Japan
      • 7.4.5.1.1. Key market trends, growth factors and opportunities
      • 7.4.5.1.2. Market size and forecast, by Type
      • 7.4.5.1.3. Market size and forecast, by Drug Class
      • 7.4.5.1.4. Market size and forecast, by Distribution channel
      • 7.4.5.2. China
      • 7.4.5.2.1. Key market trends, growth factors and opportunities
      • 7.4.5.2.2. Market size and forecast, by Type
      • 7.4.5.2.3. Market size and forecast, by Drug Class
      • 7.4.5.2.4. Market size and forecast, by Distribution channel
      • 7.4.5.3. India
      • 7.4.5.3.1. Key market trends, growth factors and opportunities
      • 7.4.5.3.2. Market size and forecast, by Type
      • 7.4.5.3.3. Market size and forecast, by Drug Class
      • 7.4.5.3.4. Market size and forecast, by Distribution channel
      • 7.4.5.4. Australia
      • 7.4.5.4.1. Key market trends, growth factors and opportunities
      • 7.4.5.4.2. Market size and forecast, by Type
      • 7.4.5.4.3. Market size and forecast, by Drug Class
      • 7.4.5.4.4. Market size and forecast, by Distribution channel
      • 7.4.5.5. South Korea
      • 7.4.5.5.1. Key market trends, growth factors and opportunities
      • 7.4.5.5.2. Market size and forecast, by Type
      • 7.4.5.5.3. Market size and forecast, by Drug Class
      • 7.4.5.5.4. Market size and forecast, by Distribution channel
      • 7.4.5.6. Rest of Asia-Pacific
      • 7.4.5.6.1. Key market trends, growth factors and opportunities
      • 7.4.5.6.2. Market size and forecast, by Type
      • 7.4.5.6.3. Market size and forecast, by Drug Class
      • 7.4.5.6.4. Market size and forecast, by Distribution channel
  • 7.5. LAMEA
    • 7.5.1. Key trends and opportunities
    • 7.5.2. Market size and forecast, by Type
    • 7.5.3. Market size and forecast, by Drug Class
    • 7.5.4. Market size and forecast, by Distribution channel
    • 7.5.5. Market size and forecast, by country
      • 7.5.5.1. Brazil
      • 7.5.5.1.1. Key market trends, growth factors and opportunities
      • 7.5.5.1.2. Market size and forecast, by Type
      • 7.5.5.1.3. Market size and forecast, by Drug Class
      • 7.5.5.1.4. Market size and forecast, by Distribution channel
      • 7.5.5.2. Saudi Arabia
      • 7.5.5.2.1. Key market trends, growth factors and opportunities
      • 7.5.5.2.2. Market size and forecast, by Type
      • 7.5.5.2.3. Market size and forecast, by Drug Class
      • 7.5.5.2.4. Market size and forecast, by Distribution channel
      • 7.5.5.3. South Africa
      • 7.5.5.3.1. Key market trends, growth factors and opportunities
      • 7.5.5.3.2. Market size and forecast, by Type
      • 7.5.5.3.3. Market size and forecast, by Drug Class
      • 7.5.5.3.4. Market size and forecast, by Distribution channel
      • 7.5.5.4. Rest of LAMEA
      • 7.5.5.4.1. Key market trends, growth factors and opportunities
      • 7.5.5.4.2. Market size and forecast, by Type
      • 7.5.5.4.3. Market size and forecast, by Drug Class
      • 7.5.5.4.4. Market size and forecast, by Distribution channel

CHAPTER 8: COMPETITIVE LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top winning strategies
  • 8.3. Product Mapping of Top 10 Player
  • 8.4. Competitive Dashboard
  • 8.5. Competitive Heatmap
  • 8.6. Top player positioning, 2021

CHAPTER 9: COMPANY PROFILES

  • 9.1. Abbvie Inc
    • 9.1.1. Company overview
    • 9.1.2. Key Executives
    • 9.1.3. Company snapshot
    • 9.1.4. Operating business segments
    • 9.1.5. Product portfolio
    • 9.1.6. Business performance
    • 9.1.7. Key strategic moves and developments
  • 9.2. Amgen Inc.
    • 9.2.1. Company overview
    • 9.2.2. Key Executives
    • 9.2.3. Company snapshot
    • 9.2.4. Operating business segments
    • 9.2.5. Product portfolio
    • 9.2.6. Business performance
    • 9.2.7. Key strategic moves and developments
  • 9.3. Pfizer Inc.
    • 9.3.1. Company overview
    • 9.3.2. Key Executives
    • 9.3.3. Company snapshot
    • 9.3.4. Operating business segments
    • 9.3.5. Product portfolio
    • 9.3.6. Business performance
    • 9.3.7. Key strategic moves and developments
  • 9.4. Novartis AG
    • 9.4.1. Company overview
    • 9.4.2. Key Executives
    • 9.4.3. Company snapshot
    • 9.4.4. Operating business segments
    • 9.4.5. Product portfolio
    • 9.4.6. Business performance
  • 9.5. Gilead Sciences, Inc.
    • 9.5.1. Company overview
    • 9.5.2. Key Executives
    • 9.5.3. Company snapshot
    • 9.5.4. Operating business segments
    • 9.5.5. Product portfolio
    • 9.5.6. Business performance
    • 9.5.7. Key strategic moves and developments
  • 9.6. Bristol-Myers Squibb Company
    • 9.6.1. Company overview
    • 9.6.2. Key Executives
    • 9.6.3. Company snapshot
    • 9.6.4. Operating business segments
    • 9.6.5. Product portfolio
    • 9.6.6. Business performance
    • 9.6.7. Key strategic moves and developments
  • 9.7. Sanofi
    • 9.7.1. Company overview
    • 9.7.2. Key Executives
    • 9.7.3. Company snapshot
    • 9.7.4. Operating business segments
    • 9.7.5. Product portfolio
    • 9.7.6. Business performance
  • 9.8. Teva Pharmaceutical Industries Limited
    • 9.8.1. Company overview
    • 9.8.2. Key Executives
    • 9.8.3. Company snapshot
    • 9.8.4. Operating business segments
    • 9.8.5. Product portfolio
    • 9.8.6. Business performance
  • 9.9. Lupin
    • 9.9.1. Company overview
    • 9.9.2. Key Executives
    • 9.9.3. Company snapshot
    • 9.9.4. Operating business segments
    • 9.9.5. Product portfolio
    • 9.9.6. Business performance
  • 9.10. Takeda Pharmaceutical Company Limited
    • 9.10.1. Company overview
    • 9.10.2. Key Executives
    • 9.10.3. Company snapshot
    • 9.10.4. Operating business segments
    • 9.10.5. Product portfolio
    • 9.10.6. Business performance
    • 9.10.7. Key strategic moves and developments

LIST OF TABLES

  • TABLE 01. GLOBAL LEUKEMIA THERAPEUTICS MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 02. LEUKEMIA THERAPEUTICS MARKET FOR ACUTE LYMPHOCYTIC LEUKEMIA, BY REGION, 2021-2031 ($MILLION)
  • TABLE 03. LEUKEMIA THERAPEUTICS MARKET FOR ACUTE MYELOID LEUKEMIA, BY REGION, 2021-2031 ($MILLION)
  • TABLE 04. LEUKEMIA THERAPEUTICS MARKET FOR CHRONIC LYMPHOCYTIC LEUKEMIA, BY REGION, 2021-2031 ($MILLION)
  • TABLE 05. LEUKEMIA THERAPEUTICS MARKET FOR CHRONIC MYELOID LEUKEMIA, BY REGION, 2021-2031 ($MILLION)
  • TABLE 06. LEUKEMIA THERAPEUTICS MARKET FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 07. GLOBAL LEUKEMIA THERAPEUTICS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 08. LEUKEMIA THERAPEUTICS MARKET FOR CHEMOTHERAPY, BY REGION, 2021-2031 ($MILLION)
  • TABLE 09. LEUKEMIA THERAPEUTICS MARKET FOR TARGETED THERAPY AND IMMUNOTHERAPY, BY REGION, 2021-2031 ($MILLION)
  • TABLE 10. GLOBAL LEUKEMIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 11. LEUKEMIA THERAPEUTICS MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2021-2031 ($MILLION)
  • TABLE 12. LEUKEMIA THERAPEUTICS MARKET FOR DRUG STORE AND RETAIL PHARMACIES, BY REGION, 2021-2031 ($MILLION)
  • TABLE 13. LEUKEMIA THERAPEUTICS MARKET FOR ONLINE PROVIDERS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 14. LEUKEMIA THERAPEUTICS MARKET, BY REGION, 2021-2031 ($MILLION)
  • TABLE 15. NORTH AMERICA LEUKEMIA THERAPEUTICS MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 16. NORTH AMERICA LEUKEMIA THERAPEUTICS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 17. NORTH AMERICA LEUKEMIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 18. NORTH AMERICA LEUKEMIA THERAPEUTICS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 19. U.S. LEUKEMIA THERAPEUTICS MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 20. U.S. LEUKEMIA THERAPEUTICS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 21. U.S. LEUKEMIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 22. CANADA LEUKEMIA THERAPEUTICS MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 23. CANADA LEUKEMIA THERAPEUTICS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 24. CANADA LEUKEMIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 25. MEXICO LEUKEMIA THERAPEUTICS MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 26. MEXICO LEUKEMIA THERAPEUTICS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 27. MEXICO LEUKEMIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 28. EUROPE LEUKEMIA THERAPEUTICS MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 29. EUROPE LEUKEMIA THERAPEUTICS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 30. EUROPE LEUKEMIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 31. EUROPE LEUKEMIA THERAPEUTICS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 32. GERMANY LEUKEMIA THERAPEUTICS MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 33. GERMANY LEUKEMIA THERAPEUTICS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 34. GERMANY LEUKEMIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 35. FRANCE LEUKEMIA THERAPEUTICS MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 36. FRANCE LEUKEMIA THERAPEUTICS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 37. FRANCE LEUKEMIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 38. UK LEUKEMIA THERAPEUTICS MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 39. UK LEUKEMIA THERAPEUTICS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 40. UK LEUKEMIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 41. ITALY LEUKEMIA THERAPEUTICS MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 42. ITALY LEUKEMIA THERAPEUTICS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 43. ITALY LEUKEMIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 44. SPAIN LEUKEMIA THERAPEUTICS MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 45. SPAIN LEUKEMIA THERAPEUTICS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 46. SPAIN LEUKEMIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 47. REST OF EUROPE LEUKEMIA THERAPEUTICS MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 48. REST OF EUROPE LEUKEMIA THERAPEUTICS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 49. REST OF EUROPE LEUKEMIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 50. ASIA-PACIFIC LEUKEMIA THERAPEUTICS MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 51. ASIA-PACIFIC LEUKEMIA THERAPEUTICS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 52. ASIA-PACIFIC LEUKEMIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 53. ASIA-PACIFIC LEUKEMIA THERAPEUTICS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 54. JAPAN LEUKEMIA THERAPEUTICS MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 55. JAPAN LEUKEMIA THERAPEUTICS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 56. JAPAN LEUKEMIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 57. CHINA LEUKEMIA THERAPEUTICS MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 58. CHINA LEUKEMIA THERAPEUTICS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 59. CHINA LEUKEMIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 60. INDIA LEUKEMIA THERAPEUTICS MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 61. INDIA LEUKEMIA THERAPEUTICS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 62. INDIA LEUKEMIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 63. AUSTRALIA LEUKEMIA THERAPEUTICS MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 64. AUSTRALIA LEUKEMIA THERAPEUTICS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 65. AUSTRALIA LEUKEMIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 66. SOUTH KOREA LEUKEMIA THERAPEUTICS MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 67. SOUTH KOREA LEUKEMIA THERAPEUTICS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 68. SOUTH KOREA LEUKEMIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 69. REST OF ASIA-PACIFIC LEUKEMIA THERAPEUTICS MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 70. REST OF ASIA-PACIFIC LEUKEMIA THERAPEUTICS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 71. REST OF ASIA-PACIFIC LEUKEMIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 72. LAMEA LEUKEMIA THERAPEUTICS MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 73. LAMEA LEUKEMIA THERAPEUTICS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 74. LAMEA LEUKEMIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 75. LAMEA LEUKEMIA THERAPEUTICS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 76. BRAZIL LEUKEMIA THERAPEUTICS MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 77. BRAZIL LEUKEMIA THERAPEUTICS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 78. BRAZIL LEUKEMIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 79. SAUDI ARABIA LEUKEMIA THERAPEUTICS MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 80. SAUDI ARABIA LEUKEMIA THERAPEUTICS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 81. SAUDI ARABIA LEUKEMIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 82. SOUTH AFRICA LEUKEMIA THERAPEUTICS MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 83. SOUTH AFRICA LEUKEMIA THERAPEUTICS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 84. SOUTH AFRICA LEUKEMIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 85. REST OF LAMEA LEUKEMIA THERAPEUTICS MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 86. REST OF LAMEA LEUKEMIA THERAPEUTICS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 87. REST OF LAMEA LEUKEMIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 88. ABBVIE INC: KEY EXECUTIVES
  • TABLE 89. ABBVIE INC: COMPANY SNAPSHOT
  • TABLE 90. ABBVIE INC: PRODUCT SEGMENTS
  • TABLE 91. ABBVIE INC: PRODUCT PORTFOLIO
  • TABLE 92. ABBVIE INC: KEY STRATERGIES
  • TABLE 93. AMGEN INC.: KEY EXECUTIVES
  • TABLE 94. AMGEN INC.: COMPANY SNAPSHOT
  • TABLE 95. AMGEN INC.: PRODUCT SEGMENTS
  • TABLE 96. AMGEN INC.: PRODUCT PORTFOLIO
  • TABLE 97. AMGEN INC.: KEY STRATERGIES
  • TABLE 98. PFIZER INC.: KEY EXECUTIVES
  • TABLE 99. PFIZER INC.: COMPANY SNAPSHOT
  • TABLE 100. PFIZER INC.: PRODUCT SEGMENTS
  • TABLE 101. PFIZER INC.: PRODUCT PORTFOLIO
  • TABLE 102. PFIZER INC.: KEY STRATERGIES
  • TABLE 103. NOVARTIS AG: KEY EXECUTIVES
  • TABLE 104. NOVARTIS AG: COMPANY SNAPSHOT
  • TABLE 105. NOVARTIS AG: PRODUCT SEGMENTS
  • TABLE 106. NOVARTIS AG: PRODUCT PORTFOLIO
  • TABLE 107. GILEAD SCIENCES, INC.: KEY EXECUTIVES
  • TABLE 108. GILEAD SCIENCES, INC.: COMPANY SNAPSHOT
  • TABLE 109. GILEAD SCIENCES, INC.: PRODUCT SEGMENTS
  • TABLE 110. GILEAD SCIENCES, INC.: PRODUCT PORTFOLIO
  • TABLE 111. GILEAD SCIENCES, INC.: KEY STRATERGIES
  • TABLE 112. BRISTOL-MYERS SQUIBB COMPANY: KEY EXECUTIVES
  • TABLE 113. BRISTOL-MYERS SQUIBB COMPANY: COMPANY SNAPSHOT
  • TABLE 114. BRISTOL-MYERS SQUIBB COMPANY: PRODUCT SEGMENTS
  • TABLE 115. BRISTOL-MYERS SQUIBB COMPANY: PRODUCT PORTFOLIO
  • TABLE 116. BRISTOL-MYERS SQUIBB COMPANY: KEY STRATERGIES
  • TABLE 117. SANOFI: KEY EXECUTIVES
  • TABLE 118. SANOFI: COMPANY SNAPSHOT
  • TABLE 119. SANOFI: PRODUCT SEGMENTS
  • TABLE 120. SANOFI: PRODUCT PORTFOLIO
  • TABLE 121. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: KEY EXECUTIVES
  • TABLE 122. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: COMPANY SNAPSHOT
  • TABLE 123. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCT SEGMENTS
  • TABLE 124. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCT PORTFOLIO
  • TABLE 125. LUPIN: KEY EXECUTIVES
  • TABLE 126. LUPIN: COMPANY SNAPSHOT
  • TABLE 127. LUPIN: PRODUCT SEGMENTS
  • TABLE 128. LUPIN: PRODUCT PORTFOLIO
  • TABLE 129. TAKEDA PHARMACEUTICAL COMPANY LIMITED: KEY EXECUTIVES
  • TABLE 130. TAKEDA PHARMACEUTICAL COMPANY LIMITED: COMPANY SNAPSHOT
  • TABLE 131. TAKEDA PHARMACEUTICAL COMPANY LIMITED: PRODUCT SEGMENTS
  • TABLE 132. TAKEDA PHARMACEUTICAL COMPANY LIMITED: PRODUCT PORTFOLIO
  • TABLE 133. TAKEDA PHARMACEUTICAL COMPANY LIMITED: KEY STRATERGIES

LIST OF FIGURES

  • FIGURE 01. LEUKEMIA THERAPEUTICS MARKET, 2021-2031
  • FIGURE 02. SEGMENTATION OF LEUKEMIA THERAPEUTICS MARKET, 2021-2031
  • FIGURE 03. TOP INVESTMENT POCKETS IN LEUKEMIA THERAPEUTICS MARKET (2022-2031)
  • FIGURE 04. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 05. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 06. MODERATE THREAT OF SUBSTITUTES
  • FIGURE 07. HIGH THREAT OF NEW ENTRANTS
  • FIGURE 08. MODERATE INTENSITY OF RIVALRY
  • FIGURE 09. DRIVERS, RESTRAINTS AND OPPORTUNITIES: GLOBALLEUKEMIA THERAPEUTICS MARKET
  • FIGURE 10. LEUKEMIA THERAPEUTICS MARKET, BY TYPE, 2021(%)
  • FIGURE 11. COMPARATIVE SHARE ANALYSIS OF LEUKEMIA THERAPEUTICS MARKET FOR ACUTE LYMPHOCYTIC LEUKEMIA, BY COUNTRY 2021-2031(%)
  • FIGURE 12. COMPARATIVE SHARE ANALYSIS OF LEUKEMIA THERAPEUTICS MARKET FOR ACUTE MYELOID LEUKEMIA, BY COUNTRY 2021-2031(%)
  • FIGURE 13. COMPARATIVE SHARE ANALYSIS OF LEUKEMIA THERAPEUTICS MARKET FOR CHRONIC LYMPHOCYTIC LEUKEMIA, BY COUNTRY 2021-2031(%)
  • FIGURE 14. COMPARATIVE SHARE ANALYSIS OF LEUKEMIA THERAPEUTICS MARKET FOR CHRONIC MYELOID LEUKEMIA, BY COUNTRY 2021-2031(%)
  • FIGURE 15. COMPARATIVE SHARE ANALYSIS OF LEUKEMIA THERAPEUTICS MARKET FOR OTHERS, BY COUNTRY 2021-2031(%)
  • FIGURE 16. LEUKEMIA THERAPEUTICS MARKET, BY DRUG CLASS, 2021(%)
  • FIGURE 17. COMPARATIVE SHARE ANALYSIS OF LEUKEMIA THERAPEUTICS MARKET FOR CHEMOTHERAPY, BY COUNTRY 2021-2031(%)
  • FIGURE 18. COMPARATIVE SHARE ANALYSIS OF LEUKEMIA THERAPEUTICS MARKET FOR TARGETED THERAPY AND IMMUNOTHERAPY, BY COUNTRY 2021-2031(%)
  • FIGURE 19. LEUKEMIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2021(%)
  • FIGURE 20. COMPARATIVE SHARE ANALYSIS OF LEUKEMIA THERAPEUTICS MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY 2021-2031(%)
  • FIGURE 21. COMPARATIVE SHARE ANALYSIS OF LEUKEMIA THERAPEUTICS MARKET FOR DRUG STORE AND RETAIL PHARMACIES, BY COUNTRY 2021-2031(%)
  • FIGURE 22. COMPARATIVE SHARE ANALYSIS OF LEUKEMIA THERAPEUTICS MARKET FOR ONLINE PROVIDERS, BY COUNTRY 2021-2031(%)
  • FIGURE 23. LEUKEMIA THERAPEUTICS MARKET BY REGION, 2021
  • FIGURE 24. U.S. LEUKEMIA THERAPEUTICS MARKET, 2021-2031 ($MILLION)
  • FIGURE 25. CANADA LEUKEMIA THERAPEUTICS MARKET, 2021-2031 ($MILLION)
  • FIGURE 26. MEXICO LEUKEMIA THERAPEUTICS MARKET, 2021-2031 ($MILLION)
  • FIGURE 27. GERMANY LEUKEMIA THERAPEUTICS MARKET, 2021-2031 ($MILLION)
  • FIGURE 28. FRANCE LEUKEMIA THERAPEUTICS MARKET, 2021-2031 ($MILLION)
  • FIGURE 29. UK LEUKEMIA THERAPEUTICS MARKET, 2021-2031 ($MILLION)
  • FIGURE 30. ITALY LEUKEMIA THERAPEUTICS MARKET, 2021-2031 ($MILLION)
  • FIGURE 31. SPAIN LEUKEMIA THERAPEUTICS MARKET, 2021-2031 ($MILLION)
  • FIGURE 32. REST OF EUROPE LEUKEMIA THERAPEUTICS MARKET, 2021-2031 ($MILLION)
  • FIGURE 33. JAPAN LEUKEMIA THERAPEUTICS MARKET, 2021-2031 ($MILLION)
  • FIGURE 34. CHINA LEUKEMIA THERAPEUTICS MARKET, 2021-2031 ($MILLION)
  • FIGURE 35. INDIA LEUKEMIA THERAPEUTICS MARKET, 2021-2031 ($MILLION)
  • FIGURE 36. AUSTRALIA LEUKEMIA THERAPEUTICS MARKET, 2021-2031 ($MILLION)
  • FIGURE 37. SOUTH KOREA LEUKEMIA THERAPEUTICS MARKET, 2021-2031 ($MILLION)
  • FIGURE 38. REST OF ASIA-PACIFIC LEUKEMIA THERAPEUTICS MARKET, 2021-2031 ($MILLION)
  • FIGURE 39. BRAZIL LEUKEMIA THERAPEUTICS MARKET, 2021-2031 ($MILLION)
  • FIGURE 40. SAUDI ARABIA LEUKEMIA THERAPEUTICS MARKET, 2021-2031 ($MILLION)
  • FIGURE 41. SOUTH AFRICA LEUKEMIA THERAPEUTICS MARKET, 2021-2031 ($MILLION)
  • FIGURE 42. REST OF LAMEA LEUKEMIA THERAPEUTICS MARKET, 2021-2031 ($MILLION)
  • FIGURE 43. TOP WINNING STRATEGIES, BY YEAR
  • FIGURE 44. TOP WINNING STRATEGIES, BY DEVELOPMENT
  • FIGURE 45. TOP WINNING STRATEGIES, BY COMPANY
  • FIGURE 46. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 47. COMPETITIVE DASHBOARD
  • FIGURE 48. COMPETITIVE HEATMAP: LEUKEMIA THERAPEUTICS MARKET
  • FIGURE 49. TOP PLAYER POSITIONING, 2021
  • FIGURE 50. ABBVIE INC: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 51. ABBVIE INC: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 52. ABBVIE INC: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 53. AMGEN INC.: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 54. AMGEN INC.: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 55. PFIZER INC.: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 56. PFIZER INC.: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 57. PFIZER INC.: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 58. NOVARTIS AG: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 59. NOVARTIS AG: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 60. NOVARTIS AG: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 61. GILEAD SCIENCES, INC.: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 62. BRISTOL-MYERS SQUIBB COMPANY: NET SALES, 2019-2021 ($MILLION)
  • FIGURE 63. BRISTOL-MYERS SQUIBB COMPANY: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 64. SANOFI: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 65. SANOFI: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 66. SANOFI: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 67. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 68. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 69. LUPIN: NET SALES, 2019-2021 ($MILLION)
  • FIGURE 70. LUPIN: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 71. TAKEDA PHARMACEUTICAL COMPANY LIMITED: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 72. TAKEDA PHARMACEUTICAL COMPANY LIMITED: REVENUE SHARE BY REGION, 2021 (%)